NASDAQ:OMED - OncoMed Pharmaceuticals Stock Price, Price Target & More

$2.50 -0.42 (-14.38 %)
(As of 04/24/2018 02:06 PM ET)
Previous Close$2.92
Today's Range$2.50 - $2.93
52-Week Range$1.74 - $5.56
Volume200,729 shs
Average Volume209,506 shs
Market Capitalization$120.90 million
P/E Ratio-2.81
Dividend YieldN/A
Beta1.81

About OncoMed Pharmaceuticals (NASDAQ:OMED)

OncoMed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand. The company has strategic alliances with GlaxoSmithKline LLC to develop and commercialize antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

Receive OMED News and Ratings via Email

Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200

Debt

Debt-to-Equity RatioN/A
Current Ratio1.13%
Quick Ratio1.13%

Price-To-Earnings

Trailing P/E Ratio-2.81
Forward P/E Ratio-2.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$38.15 million
Price / Sales2.51
Cash FlowN/A
Price / CashN/A
Book Value($1.28) per share
Price / Book-1.95

Profitability

EPS (Most Recent Fiscal Year)($1.04)
Net Income$-39,060,000.00
Net Margins-102.38%
Return on EquityN/A
Return on Assets-29.09%

Miscellaneous

Employees56
Outstanding Shares38,260,000

How to Become a New Pot Stock Millionaire

OncoMed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions

What is OncoMed Pharmaceuticals' stock symbol?

OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

How were OncoMed Pharmaceuticals' earnings last quarter?

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) posted its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.59. The biopharmaceutical company had revenue of $20.64 million for the quarter, compared to analysts' expectations of $5.10 million. View OncoMed Pharmaceuticals' Earnings History.

When is OncoMed Pharmaceuticals' next earnings date?

OncoMed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for OncoMed Pharmaceuticals.

What price target have analysts set for OMED?

5 analysts have issued 12 month price targets for OncoMed Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they anticipate OncoMed Pharmaceuticals' share price to reach $4.60 in the next twelve months. View Analyst Ratings for OncoMed Pharmaceuticals.

What are Wall Street analysts saying about OncoMed Pharmaceuticals stock?

Here are some recent quotes from research analysts about OncoMed Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (3/14/2018)
  • 2. Cantor Fitzgerald analysts commented, "Restructuring plan should lengthen cash runway by at least a year, and we view a focus on assets with potential milestone opportunities as a positive given." (4/25/2017)

Who are some of OncoMed Pharmaceuticals' key competitors?

Who are OncoMed Pharmaceuticals' key executives?

OncoMed Pharmaceuticals' management team includes the folowing people:
  • Mr. Perry A. Karsen, Exec. Chairman (Age 63)
  • Dr. John A. Lewicki, Pres (Age 66)
  • Dr. Austin Gurney Ph.D., Chief Scientific Officer & Sr. VP (Age 54)
  • Michelle Corral, Sr. Director of Investor Relations and Corp. Communications
  • Dr. Alicia J. Hager J.D., Ph.D., Sr. VP and Gen. Counsel (Age 48)

Has OncoMed Pharmaceuticals been receiving favorable news coverage?

News coverage about OMED stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoMed Pharmaceuticals earned a daily sentiment score of 0.07 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.44 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of OncoMed Pharmaceuticals?

Shares of OMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoMed Pharmaceuticals' stock price today?

One share of OMED stock can currently be purchased for approximately $2.51.

How big of a company is OncoMed Pharmaceuticals?

OncoMed Pharmaceuticals has a market capitalization of $120.90 million and generates $38.15 million in revenue each year. The biopharmaceutical company earns $-39,060,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. OncoMed Pharmaceuticals employs 56 workers across the globe.

How can I contact OncoMed Pharmaceuticals?

OncoMed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]


MarketBeat Community Rating for OncoMed Pharmaceuticals (OMED)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  407
MarketBeat's community ratings are surveys of what our community members think about OncoMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OncoMed Pharmaceuticals (NASDAQ:OMED) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for OncoMed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.60, suggesting that the stock has a possible upside of 84.00%. The high price target for OMED is $6.00 and the low price target for OMED is $3.00. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.132.252.25
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.60$5.5714$6.00$6.00
Price Target Upside: 84.00% upside80.89% upside50.75% upside37.30% upside

OncoMed Pharmaceuticals (NASDAQ:OMED) Consensus Price Target History

Price Target History for OncoMed Pharmaceuticals (NASDAQ:OMED)

OncoMed Pharmaceuticals (NASDAQ:OMED) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018HC WainwrightReiterated RatingHold$3.00HighView Rating Details
1/4/2018Cantor FitzgeraldSet Price TargetHold$6.00HighView Rating Details
10/6/2017SunTrust BanksReiterated RatingHold$4.00N/AView Rating Details
9/28/2017Jefferies GroupReiterated RatingBuy$5.00LowView Rating Details
7/10/2017Piper JaffraySet Price TargetHold$5.00MediumView Rating Details
4/17/2017JMP SecuritiesDowngradeOutperform -> Market PerformLowView Rating Details
4/11/2017Leerink SwannBoost Price TargetMarket Perform$6.00 -> $10.00HighView Rating Details
4/11/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$6.00HighView Rating Details
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

OncoMed Pharmaceuticals (NASDAQ:OMED) Earnings History and Estimates Chart

Earnings by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)

OncoMed Pharmaceuticals (NASDAQ:OMED) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-1.13 EPS

OncoMed Pharmaceuticals (NASDAQ OMED) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018N/AView Earnings Details
3/8/2018Q4 2017($0.34)$0.25$5.10 million$20.64 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.41)($0.28)$6.25 million$5.11 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.40)$6.08 million$6.20 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.62)($0.61)$5.85 million$6.20 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.68)($0.60)$6.57 million$6.22 millionViewListenView Earnings Details
11/1/2016Q3($0.77)($0.77)$9.48 million$5.92 millionViewN/AView Earnings Details
8/9/2016Q216($0.81)($0.91)$8.09 million$6.67 millionViewN/AView Earnings Details
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details
11/4/2014($0.30)($0.18)$17.84 million$19.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.47)$18.08 million$6.02 millionViewN/AView Earnings Details
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details
11/12/2013Q3$0.12($0.15)$17.21 million$12.90 millionViewN/AView Earnings Details
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

OncoMed Pharmaceuticals (NASDAQ:OMED) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

OncoMed Pharmaceuticals (NASDAQ OMED) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.80%
Institutional Ownership Percentage: 53.62%
Insider Trading History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Insider Trading History for OncoMed Pharmaceuticals (NASDAQ:OMED)

OncoMed Pharmaceuticals (NASDAQ OMED) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/10/2017Alicia J HagerSVPSell1,248$4.24$5,291.52View SEC Filing  
10/10/2017Paul J HastingsCEOSell1,398$4.24$5,927.52View SEC Filing  
6/5/2017Perry A KarsenDirectorBuy10,000$3.46$34,600.0010,000View SEC Filing  
5/26/2017Jonathan D RootDirectorSell13,880$3.71$51,494.80121,020View SEC Filing  
5/25/2017Jack W LasersohnDirectorBuy34,614$3.37$116,649.18185,709View SEC Filing  
5/23/2017Jack W LasersohnDirectorBuy20,000$3.55$71,000.00151,095View SEC Filing  
5/19/2017Jonathan D RootDirectorSell7,487$3.70$27,701.90121,020View SEC Filing  
5/16/2017Jack W LasersohnDirectorBuy23,507$3.49$82,039.43131,095View SEC Filing  
4/4/2017Alicia J. HagerSVPSell4,316$9.06$39,102.96View SEC Filing  
4/4/2017Paul J. HastingsCEOSell6,473$9.06$58,645.38View SEC Filing  
4/4/2017Sunil PatelInsiderSell5,754$9.06$52,131.24View SEC Filing  
1/6/2017Paul J. HastingsCEOSell42,738$8.34$356,434.92View SEC Filing  
1/3/2017John A. LewickiEVPSell9,175$7.63$70,005.25View SEC Filing  
1/3/2017Timothy HoeySVPSell12,763$7.64$97,509.32View SEC Filing  
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.0020,642View SEC Filing  
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.4413,377View SEC Filing  
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.3617,838View SEC Filing  
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.3622,025View SEC Filing  
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.0015,000View SEC Filing  
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.0015,000View SEC Filing  
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.0035,419View SEC Filing  
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.0022,804View SEC Filing  
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.1046,560View SEC Filing  
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.0035,350View SEC Filing  
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.0035,350View SEC Filing  
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OncoMed Pharmaceuticals (NASDAQ OMED) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) Will Post Quarterly Sales of $6.51 MillionZacks: Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) Will Post Quarterly Sales of $6.51 Million
www.americanbankingnews.com - April 23 at 4:14 AM
-$0.24 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter-$0.24 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 21 at 11:12 AM
OncoMed Pharmaceuticals (OMED) Given a $5.00 Price Target by Piper Jaffray AnalystsOncoMed Pharmaceuticals (OMED) Given a $5.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 19 at 12:16 PM
OncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACROncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACR
www.streetinsider.com - April 19 at 10:07 AM
OncoMed Pharmaceuticals, Inc. (OMED) Receives Average Recommendation of "Hold" from AnalystsOncoMed Pharmaceuticals, Inc. (OMED) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 19 at 9:13 AM
OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual MeetingOncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 18 at 10:06 AM
OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual MeetingOncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 9 at 10:21 AM
$6.51 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter$6.51 Million in Sales Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 6 at 3:42 AM
-$0.24 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter-$0.24 Earnings Per Share Expected for OncoMed Pharmaceuticals, Inc. (OMED) This Quarter
www.americanbankingnews.com - April 4 at 11:46 AM
Oncomed Pharmaceuticals (OMED) Lifted to Buy at Zacks Investment ResearchOncomed Pharmaceuticals (OMED) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM
Oncomed Pharmaceuticals (OMED) Downgraded to Hold at Zacks Investment ResearchOncomed Pharmaceuticals (OMED) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 9:24 PM
Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?
finance.yahoo.com - March 27 at 4:11 PM
Oncomed Pharmaceuticals Inc (OMED) Receives Average Rating of "Hold" from AnalystsOncomed Pharmaceuticals Inc (OMED) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 25 at 7:58 AM
$6.51 Million in Sales Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter$6.51 Million in Sales Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - March 20 at 5:52 AM
BRIEF-OncoMed Announces Appointment Of John Lewicki As CEOBRIEF-OncoMed Announces Appointment Of John Lewicki As CEO
www.reuters.com - March 19 at 4:14 PM
OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of DirectorsOncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors
finance.yahoo.com - March 19 at 10:36 AM
Oncomed Pharmaceuticals (OMED) Raised to "Buy" at Zacks Investment ResearchOncomed Pharmaceuticals (OMED) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 17 at 11:46 PM
OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects?OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects?
finance.yahoo.com - March 16 at 4:13 PM
Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy NowCatalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
finance.yahoo.com - March 14 at 4:08 PM
HC Wainwright Reaffirms Hold Rating for Oncomed Pharmaceuticals (OMED)HC Wainwright Reaffirms Hold Rating for Oncomed Pharmaceuticals (OMED)
www.americanbankingnews.com - March 9 at 9:04 PM
Oncomed Pharmaceuticals (OMED) Posts  Earnings Results, Beats Expectations By $0.59 EPSOncomed Pharmaceuticals (OMED) Posts Earnings Results, Beats Expectations By $0.59 EPS
www.americanbankingnews.com - March 9 at 4:27 PM
OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational HighlightsOncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
finance.yahoo.com - March 9 at 11:54 AM
OncoMed tops Street 4Q forecastsOncoMed tops Street 4Q forecasts
finance.yahoo.com - March 9 at 11:54 AM
When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?
finance.yahoo.com - March 9 at 11:54 AM
OncoMed Pharmaceuticals Q4 Earnings PreviewOncoMed Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - March 8 at 4:12 PM
Has OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improved Earnings Growth In Recent Times?Has OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 7 at 4:04 PM
Partner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of DirectorsPartner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of Directors
www.bizjournals.com - March 7 at 10:52 AM
 Brokerages Expect Oncomed Pharmaceuticals Inc (OMED) Will Post Quarterly Sales of $5.10 Million Brokerages Expect Oncomed Pharmaceuticals Inc (OMED) Will Post Quarterly Sales of $5.10 Million
www.americanbankingnews.com - March 3 at 1:22 PM
Oncomed Pharmaceuticals Inc (OMED) Expected to Post Earnings of -$0.31 Per ShareOncomed Pharmaceuticals Inc (OMED) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - March 1 at 11:45 AM
Oncomed Pharmaceuticals (OMED) Scheduled to Post Earnings on ThursdayOncomed Pharmaceuticals (OMED) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM
Oncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of "Hold" by BrokeragesOncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 28 at 11:57 AM
Oncomed Pharmaceuticals (OMED) "Neutral" Rating Reiterated at HC WainwrightOncomed Pharmaceuticals' (OMED) "Neutral" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - February 24 at 3:32 PM
OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018
finance.yahoo.com - February 23 at 10:19 AM
Why You Need To Look At This Factor Before Buying OncoMed Pharmaceuticals Inc (NASDAQ:OMED)Why You Need To Look At This Factor Before Buying OncoMed Pharmaceuticals Inc (NASDAQ:OMED)
finance.yahoo.com - February 21 at 10:54 AM
Zacks: Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) Will Announce Quarterly Sales of $5.10 MillionZacks: Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) Will Announce Quarterly Sales of $5.10 Million
www.americanbankingnews.com - February 14 at 5:04 AM
Oncomed Pharmaceuticals (OMED) Set to Announce Earnings on WednesdayOncomed Pharmaceuticals (OMED) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:56 AM
Organovo (ONVO) and Oncomed Pharmaceuticals (OMED) Critical ReviewOrganovo (ONVO) and Oncomed Pharmaceuticals (OMED) Critical Review
www.americanbankingnews.com - February 11 at 3:22 AM
Oncomed Pharmaceuticals Inc (OMED) Receives Average Recommendation of "Hold" from AnalystsOncomed Pharmaceuticals Inc (OMED) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 3 at 12:01 PM
What’s Installed For OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?What’s Installed For OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?
finance.yahoo.com - January 30 at 5:55 AM
Oncomed Pharmaceuticals Inc (OMED) Expected to Post Quarterly Sales of $5.10 MillionOncomed Pharmaceuticals Inc (OMED) Expected to Post Quarterly Sales of $5.10 Million
www.americanbankingnews.com - January 28 at 2:58 AM
Oncomed Pharmaceuticals Inc (OMED) Expected to Announce Earnings of -$0.31 Per ShareOncomed Pharmaceuticals Inc (OMED) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - January 26 at 5:20 PM
Oncomed Pharmaceuticals (OMED) versus Sorrento Tech (ROKA) Head-To-Head ContrastOncomed Pharmaceuticals (OMED) versus Sorrento Tech (ROKA) Head-To-Head Contrast
www.americanbankingnews.com - January 22 at 11:32 AM
What Should You Know About OncoMed Pharmaceuticals Inc’s (NASDAQ:OMED) Earnings Trajectory?What Should You Know About OncoMed Pharmaceuticals Inc’s (NASDAQ:OMED) Earnings Trajectory?
finance.yahoo.com - January 11 at 10:38 AM
 Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) to Post -$0.31 EPS Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) to Post -$0.31 EPS
www.americanbankingnews.com - January 9 at 3:42 PM
Oncomed Pharmaceuticals Inc (OMED) Given Average Rating of "Hold" by BrokeragesOncomed Pharmaceuticals Inc (OMED) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 9 at 9:58 AM
SunTrust Banks Comments on Oncomed Pharmaceuticals Incs FY2022 Earnings (OMED)SunTrust Banks Comments on Oncomed Pharmaceuticals Inc's FY2022 Earnings (OMED)
www.americanbankingnews.com - January 8 at 8:10 PM
Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - OMEDNewman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - OMED
finance.yahoo.com - January 8 at 4:46 PM
Cantor Fitzgerald Analysts Give Oncomed Pharmaceuticals (OMED) a $6.00 Price TargetCantor Fitzgerald Analysts Give Oncomed Pharmaceuticals (OMED) a $6.00 Price Target
www.americanbankingnews.com - January 7 at 12:44 AM
Oncomed Pharmaceuticals (OMED) Cut to Hold at Zacks Investment ResearchOncomed Pharmaceuticals (OMED) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 7:02 AM
BRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has ResignedBRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has Resigned
www.reuters.com - January 4 at 4:40 PM

SEC Filings

OncoMed Pharmaceuticals (NASDAQ:OMED) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OncoMed Pharmaceuticals (NASDAQ:OMED) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OncoMed Pharmaceuticals (NASDAQ OMED) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.